Acatris Extends Isoflavone IP Licenses

MINNEAPOLIS—Acatris Inc. exclusively licensed U.S. Patent No. 7,045,155 from Novogen Ltd., covering compositions of phytoestrogen-enriched extracts from soy hypocotyls for treatment of certain human health conditions. Acatris formed an exclusive agreement with Archer Daniels Midland (ADM) in 2005 to gain access to the intellectual property (IP) portfolio that included the patents licensed from Novogen for production processes and women’s health labeling claims for soy germ isoflavones.

Acatris supplies the SoyLife® range of soy isoflavone ingredients, derived from soy germ. Proprietary studies have shown its efficacy in supporting women’s health, bone health, heart health and cognitive function. “We are committed to providing consumers with the highest quality ingredients through our proprietary production technology and our expansive commitment to clinical research,” said Laurent Leduc, president, North America Health Division, Acatris (www.acatris.com).